<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737345</url>
  </required_header>
  <id_info>
    <org_study_id>00086371</org_study_id>
    <nct_id>NCT02737345</nct_id>
  </id_info>
  <brief_title>Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scott Allen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <brief_summary>
    <textblock>
      1. Further characterize the incidence of hyperfibrinolysis in cirrhotics

        2. Correlate hyperfibrinolysis with

             1. hepatitis C

             2. alcoholic liver disease

             3. the subset of a&amp;b with renal failure with and without dialysis

        3. Better describe the hyperfibrinolytic ROTEM profile in cirrhotics
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients who exhibit fibrinolysis</measure>
    <time_frame>Within 60 minutes of sample run time</time_frame>
    <description>The percentage of patients who exhibit fibrinolysis, defined as a decrease in maximum clot firmness &lt;15% within 60 minutes of sample run time.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Waiting list</arm_group_label>
    <description>Patients on the liver transplant waiting list</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rotem</intervention_name>
    <arm_group_label>Waiting list</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with liver failure who are on the liver transplant waiting list
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be on the the liver transplant waiting list

        Exclusion Criteria:

          -  liver failure without eligibility for transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Allen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Allen</last_name>
    <phone>801-205-4115205-4115</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Allen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 14, 2017</lastchanged_date>
  <firstreceived_date>April 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Scott Allen</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>fibrinolysis</keyword>
  <keyword>liver transplant</keyword>
  <keyword>thromboelastometry</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
